DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more
DiaMedica Therapeutics Inc (DMAC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.128x
Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) has a cash flow conversion efficiency ratio of -0.128x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.60 Million) by net assets ($51.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DiaMedica Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how DiaMedica Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DiaMedica Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DiaMedica Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
0.016x |
|
Kwangdong Phar
KO:009290
|
0.041x |
|
Provident Bancorp Inc
NASDAQ:PVBC
|
0.020x |
|
GD Culture Group Limited
NASDAQ:GDC
|
-0.001x |
|
Cloud Live Technology Group Co Ltd
SHE:002306
|
-0.051x |
|
Prabha Energy Limited
NSE:PRABHA
|
N/A |
|
Shandong Tongda Island New Materials Co Ltd
SHE:300321
|
-0.010x |
|
HORNBACH Baumarkt AG
HM:HBM
|
0.043x |
Annual Cash Flow Conversion Efficiency for DiaMedica Therapeutics Inc (2004–2024)
The table below shows the annual cash flow conversion efficiency of DiaMedica Therapeutics Inc from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $40.72 Million | $-22.08 Million | -0.542x | -47.81% |
| 2023-12-31 | $51.06 Million | $-18.73 Million | -0.367x | -1.42% |
| 2022-12-31 | $31.83 Million | $-11.51 Million | -0.362x | -29.96% |
| 2021-12-31 | $44.02 Million | $-12.25 Million | -0.278x | +21.18% |
| 2020-12-31 | $26.01 Million | $-9.19 Million | -0.353x | +70.45% |
| 2019-12-31 | $7.62 Million | $-9.10 Million | -1.195x | -257.17% |
| 2018-12-31 | $17.02 Million | $-5.70 Million | -0.335x | +93.15% |
| 2017-12-31 | $799.00K | $-3.90 Million | -4.881x | -101.17% |
| 2016-12-31 | $1.25 Million | $-3.02 Million | -2.426x | -318.40% |
| 2015-12-31 | $-1.23 Million | $-1.37 Million | 1.111x | -54.77% |
| 2014-12-31 | $-1.53 Million | $-3.76 Million | 2.456x | +161.68% |
| 2013-12-31 | $1.38 Million | $-5.50 Million | -3.983x | -64.48% |
| 2012-12-31 | $2.26 Million | $-5.48 Million | -2.421x | -320.16% |
| 2011-12-31 | $5.96 Million | $-3.44 Million | -0.576x | -106.67% |
| 2010-12-31 | $8.52 Million | $-2.38 Million | -0.279x | +86.39% |
| 2009-12-31 | $1.05 Million | $-2.15 Million | -2.049x | -288.44% |
| 2008-12-31 | $2.78 Million | $-1.47 Million | -0.528x | -76.73% |
| 2007-12-31 | $4.06 Million | $-1.21 Million | -0.299x | +75.65% |
| 2006-12-31 | $653.60K | $-801.16K | -1.226x | +25.36% |
| 2005-12-31 | $506.11K | $-831.17K | -1.642x | -1852.50% |
| 2004-12-31 | $-1.06 Million | $-99.35K | 0.094x | -- |